556 related articles for article (PubMed ID: 12877363)
1. Monitoring of a single post-infusion blood sample to estimate the actual peak and trough concentration of tobramycin in critically ill patients.
Reimann IR; Meier-Hellmann A; Traut T; Reinhart K; Hoffmann A
Exp Toxicol Pathol; 2003 Jun; 54(5-6):493-8. PubMed ID: 12877363
[TBL] [Abstract][Full Text] [Related]
2. [Serum level-adjusted dosage of once-daily aminoglycoside therapy in critical illness: results of a prospective study].
Reimann IR; Meier-Hellmann A; Pfeifer R; Traut T; Schilling A; Stein G; Reinhart K; Hoffmann A
Anasthesiol Intensivmed Notfallmed Schmerzther; 1999 May; 34(5):288-95. PubMed ID: 10372218
[TBL] [Abstract][Full Text] [Related]
3. Extended-interval dosing of tobramycin in neonates: implications for therapeutic drug monitoring.
de Hoog M; Mouton JW; Schoemaker RC; Verduin CM; van den Anker JN
Clin Pharmacol Ther; 2002 May; 71(5):349-58. PubMed ID: 12011820
[TBL] [Abstract][Full Text] [Related]
4. Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
Buijk SE; Mouton JW; Gyssens IC; Verbrugh HA; Bruining HA
Intensive Care Med; 2002 Jul; 28(7):936-42. PubMed ID: 12122533
[TBL] [Abstract][Full Text] [Related]
5. Suboptimal aminoglycoside dosing in critically ill patients.
Rea RS; Capitano B; Bies R; Bigos KL; Smith R; Lee H
Ther Drug Monit; 2008 Dec; 30(6):674-81. PubMed ID: 19057371
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic variability of extended interval tobramycin in burn patients.
Bracco D; Landry C; Dubois MJ; Eggimann P
Burns; 2008 Sep; 34(6):791-6. PubMed ID: 18395988
[TBL] [Abstract][Full Text] [Related]
7. Tobramycin population pharmacokinetics in neonates.
de Hoog M; Schoemaker RC; Mouton JW; van den Anker JN
Clin Pharmacol Ther; 1997 Oct; 62(4):392-9. PubMed ID: 9357390
[TBL] [Abstract][Full Text] [Related]
8. Effect of pharmacokinetic sampling methods on aminoglycoside dosing in critically ill surgery patients.
Mann HJ; Wittbrodt ET; Baghaie AA; Cerra FB
Pharmacotherapy; 1998; 18(2):371-8. PubMed ID: 9545157
[TBL] [Abstract][Full Text] [Related]
9. Exploration of once-daily dosing of aminoglycosides through Bayesian simulation.
Garrelts JC
Pharmacotherapy; 1996; 16(2):286-94. PubMed ID: 8820474
[TBL] [Abstract][Full Text] [Related]
10. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?
Roberts JA; Roberts MS; Robertson TA; Dalley AJ; Lipman J
Crit Care Med; 2009 Mar; 37(3):926-33. PubMed ID: 19237898
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic outcomes of a simplified, weight-based, extended-interval gentamicin dosing protocol in critically ill neonates.
Hoff DS; Wilcox RA; Tollefson LM; Lipnik PG; Commers AR; Liu M
Pharmacotherapy; 2009 Nov; 29(11):1297-305. PubMed ID: 19857147
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of once daily tobramycin dosing in critically ill patients through Bayesian simulation.
Peris-Marti JF; Borras-Blasco J; Rosique-Robles JD; Gonzalez-Delgado M
J Clin Pharm Ther; 2004 Feb; 29(1):65-70. PubMed ID: 14748900
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients.
Lam W; Tjon J; Seto W; Dekker A; Wong C; Atenafu E; Bitnun A; Waters V; Yau Y; Solomon M; Ratjen F
J Antimicrob Chemother; 2007 Jun; 59(6):1135-40. PubMed ID: 17446242
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients.
Delattre IK; Musuamba FT; Nyberg J; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq PE
Ther Drug Monit; 2010 Dec; 32(6):749-56. PubMed ID: 20962708
[TBL] [Abstract][Full Text] [Related]
15. Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin.
Hermida J; Tutor JC
Ther Drug Monit; 2006 Jun; 28(3):326-31. PubMed ID: 16778715
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic parameters of vancomycin in critically ill patients.
Llopis-Salvia P; Jiménez-Torres NV
J Clin Pharm Ther; 2006 Oct; 31(5):447-54. PubMed ID: 16958822
[TBL] [Abstract][Full Text] [Related]
17. Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations.
Conil JM; Georges B; Ruiz S; Rival T; Seguin T; Cougot P; Fourcade O; Pharmd GH; Saivin S
Br J Clin Pharmacol; 2011 Jan; 71(1):61-71. PubMed ID: 21143502
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept.
Roberts JA; Ulldemolins M; Roberts MS; McWhinney B; Ungerer J; Paterson DL; Lipman J
Int J Antimicrob Agents; 2010 Oct; 36(4):332-9. PubMed ID: 20685085
[TBL] [Abstract][Full Text] [Related]
19. Effect of various estimates of renal function on prediction of vancomycin concentration by the population mean and Bayesian methods.
Tsuji Y; Hiraki Y; Mizoguchi A; Sadoh S; Sonemoto E; Kamimura H; Karube Y
J Clin Pharm Ther; 2009 Aug; 34(4):465-72. PubMed ID: 19583680
[TBL] [Abstract][Full Text] [Related]
20. Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15-20 mg/L suggested by the vancomycin consensus guidelines.
Kullar R; Leonard SN; Davis SL; Delgado G; Pogue JM; Wahby KA; Falcione B; Rybak MJ
Pharmacotherapy; 2011 May; 31(5):441-8. PubMed ID: 21923425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
